Replimune Group (NASDAQ:REPL) Announces Earnings Results

Replimune Group (NASDAQ:REPL) issued its earnings results on Wednesday. The company reported ($0.79) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.70) by ($0.09), Zacks reports.

Replimune Group Price Performance

Shares of NASDAQ REPL traded up $0.28 during midday trading on Wednesday, reaching $13.13. The stock had a trading volume of 94,296 shares, compared to its average volume of 755,579. The company has a market capitalization of $898.35 million, a price-to-earnings ratio of -4.29 and a beta of 1.30. Replimune Group has a 12-month low of $4.92 and a 12-month high of $17.00. The stock has a 50-day moving average of $12.49 and a 200-day moving average of $11.64. The company has a debt-to-equity ratio of 0.18, a quick ratio of 10.11 and a current ratio of 10.11.

Analyst Upgrades and Downgrades

Several equities analysts recently issued reports on the company. HC Wainwright upped their price objective on Replimune Group from $17.00 to $21.00 and gave the company a “buy” rating in a research report on Wednesday, January 22nd. BMO Capital Markets upped their price target on shares of Replimune Group from $18.00 to $27.00 and gave the company an “outperform” rating in a research report on Wednesday, January 22nd. Finally, Jefferies Financial Group boosted their target price on shares of Replimune Group from $16.00 to $19.00 and gave the company a “buy” rating in a research report on Wednesday, December 4th. Seven equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Buy” and an average target price of $19.14.

Insider Activity at Replimune Group

In other Replimune Group news, insider Konstantinos Xynos sold 7,246 shares of the stock in a transaction that occurred on Monday, November 18th. The shares were sold at an average price of $10.78, for a total transaction of $78,111.88. Following the completion of the sale, the insider now directly owns 109,885 shares of the company’s stock, valued at $1,184,560.30. This trade represents a 6.19 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, CEO Sushil Patel sold 10,000 shares of the business’s stock in a transaction on Monday, December 16th. The stock was sold at an average price of $12.42, for a total transaction of $124,200.00. Following the completion of the transaction, the chief executive officer now directly owns 202,014 shares in the company, valued at $2,509,013.88. This trade represents a 4.72 % decrease in their position. The disclosure for this sale can be found here. 8.80% of the stock is owned by corporate insiders.

About Replimune Group

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.